Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults
Study Identifier:
ALXN1840-HV-104
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1840
Date
Jul 2019 - Oct 2019
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 45 Years
Requirements Information
Sex
Female & Male
Age
18 - 45 Years
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1840
Date
Jul 2019 - Oct 2019
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 45 Years years
Requirements Information
Protocol Summary
To assess the relative bioavailability of ALXN1840 administered orally as a single enteric-coated (EC) tablet (reference, Treatment A) versus three EC tablets (test, Treatment B).
Trial Locations
Location
Status
Location
Clinical Trial Site
London, United Kingdom, SE11YR
Status
N/A